Scope
NICE NG122 integrates lung-cancer diagnosis, staging, curative treatment assessment, small-cell treatment and supportive care. The acquired guidance includes newer technology-appraisal links alongside older core recommendations. Its original stage-based recommendations use AJCC seventh-edition terminology, which must be reconciled with the staging system used in a current treatment appraisal.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Obtain informative tissue and staging with the least risk
- Refer suspected lung cancer to a lung-cancer multidisciplinary team and discuss every working diagnosis at its meeting. Make specialist nursing support available throughout care and avoid undue delays in indicated treatment. [1]
- Obtain contrast-enhanced CT covering the chest, liver, adrenals and lower neck before biopsy, with caution in renal impairment. Choose investigations that provide diagnosis and staging information together while minimizing patient risk. [1]
- Ensure specimens permit pathological diagnosis, tumour subtyping and molecular-marker assessment without unacceptable procedural risk. Use the referenced National Genomics Test Directory to guide sequencing panels; a diagnosis alone may be insufficient for treatment selection. [1]
- Offer image-guided biopsy for peripheral lesions when it will guide treatment. Prefer biopsy of enlarged intrathoracic nodes of at least 10 mm short axis or another lesion over the primary tumour when nodal stage changes treatment; use bronchoscopy for central lesions when nodal staging will not change treatment. [1]
- Offer PET-CT before potentially curative treatment. If intrathoracic nodes are enlarged to at least 10 mm short axis in a potentially curable patient, follow PET-CT with EBUS-TBNA and/or EUS-FNA for nodal assessment. [1]
- When nodal status changes treatment, systematically sample suspicious PET-positive or enlarged nodes with EBUS-TBNA and/or EUS-FNA. Consider surgical mediastinal staging after a negative result if suspicion remains high and the result would affect the plan. [1]
- Confirm isolated distant metastasis or a synchronous tumour by biopsy or further imaging when curative treatment remains possible. Neurological features suggesting intracranial disease warrant brain MRI or CT followed by MRI if CT is normal. [1]
- For curative-intent NSCLC under this guideline’s original staging framework, do not offer dedicated brain imaging in asymptomatic clinical stage 1. Offer contrast brain CT in stage 2, followed by MRI if metastasis is suspected, and contrast brain MRI in stage 3. [1]
Assess fitness and discuss local treatment
- Encourage smoking cessation as soon as lung cancer is suspected, explaining pulmonary surgical risk, but do not postpone cancer surgery solely to allow cessation. Discuss estimated operative mortality and relevant cardiopulmonary risk before consent. [1]
- Before curative treatment, measure spirometry and transfer factor; before surgery predict postoperative lung function. Predicted postoperative FEV1 or TLCO below 30% does not automatically exclude curative treatment if the person accepts dyspnoea and complication risks. [1]
- For NSCLC patients fit for curative surgery, the guideline offers lobectomy and hilar/mediastinal node sampling or resection. More extensive surgery is reserved for obtaining clear margins; patients potentially suitable for multimodality treatment need both thoracic oncology and surgical assessment. [1]
- For stage 1–2a, T1a–T2b N0 M0 NSCLC in the guideline’s original staging, offer SABR or sublobar resection if lobectomy is declined or contraindicated. If all surgery is declined or contraindicated, offer SABR; if SABR is unsuitable, offer conventional or hyperfractionated radiotherapy. [1]
- For operable stage 3a N2 NSCLC under the source staging system, consider chemoradiotherapy with surgery only when the patient is fit for the combined approach. Discuss progression-free-survival benefit and possible overall-survival benefit; use an experienced multidisciplinary team. [1]
- Systemic treatment requires the relevant biomarker- and setting-specific appraisal. Examples linked here include adjuvant osimertinib after complete resection of stage 1b–3a EGFR exon 19 deletion or exon 21 L858R disease, stopping by 3 years or earlier for recurrence or unacceptable toxicity. [1]
- For locally advanced unresectable NSCLC, durvalumab is an appraisal-linked option when tumour PD-L1 expression is at least 1% and disease has not progressed after concurrent platinum chemoradiation. Consult the full appraisal rather than applying the label to all unresectable disease. [1]
Use small-cell-specific treatment pathways
- Arrange thoracic-oncology assessment within 1 week of deciding to recommend SCLC treatment. The guideline considers surgery only for selected early-stage T1–T2a N0 M0 SCLC under its original staging framework. [1]
- For limited-stage SCLC, offer 4–6 cycles of cisplatin-based combination chemotherapy. Consider carboplatin substitution with renal impairment, WHO performance status ≥2 or significant comorbidity. [1]
- For limited-stage SCLC, WHO performance status 0–1 and disease encompassable in radical thoracic radiotherapy, offer concurrent chemotherapy and twice-daily radiotherapy starting in the first or second cycle. Offer once-daily radiation if twice-daily treatment is declined or cannot be given. [1]
- Offer sequential radical thoracic radiotherapy to limited-stage patients who respond to chemotherapy but cannot tolerate concurrent treatment. The newer linked appraisal lists durvalumab as an option for adults with limited-stage SCLC without progression after platinum chemoradiotherapy. [1]
- For untreated extensive-stage SCLC with ECOG performance status 0–1, consult the linked appraisals for durvalumab with etoposide plus carboplatin/cisplatin, or atezolizumab with etoposide plus carboplatin. These links do not define a complete prescription or every eligibility condition. [1]
- Cranial prophylaxis differs by setting: the guideline offers it for limited-stage SCLC, WHO status 0–2, without progression after first-line therapy; it says consider it in extensive-stage disease with WHO status 0–2 after response. Discuss the potential benefit and adverse quality-of-life effects. [1]
Treat symptoms and arrange follow-up
- Offer appropriate palliative radiotherapy when curative treatment is not possible. Impending endobronchial obstruction needs early intervention with external-beam radiation and/or endobronchial debulking or stenting; troublesome effusions may benefit from drainage and selected pleurodesis. [1]
- Involve supportive and palliative-care professionals for symptoms including weight loss, swallowing difficulty and depression. Arrange specialist follow-up within 6 weeks after treatment and regular appointments thereafter; provide a route to the lung-cancer nurse between visits. [1]
Limitations and use
- Original stage-based recommendations use AJCC seventh-edition staging; do not map them directly to a different edition without checking. Linked technology appraisals and biomarker-specific advanced-NSCLC pathways are not fully reproduced here, so this is not a complete contemporary systemic-therapy selection or dosing protocol. Perioperative risk, radiation planning, molecular testing, drug safety and local access require specialist assessment.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Lung cancer: diagnosis and management
Selected recommendation material consulted
Publication details
- Issuing organisation
- NICE
- First published
- 28 March 2019
- Publisher’s latest update
- 8 March 2024
- Resource type
- Clinical guideline · House clinical summary
- Source setting
- United Kingdom
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.